Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5407)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jun 6, 2021 (publication date) through Dec 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zheng QN, Xu MY, Gan FM, Ye SS, Zhao H. Thymosin as a possible therapeutic drug for COVID-19: A case report. World J Clin Cases 2021; 9(16): 4090-4094 [PMID: 34141770 DOI: 10.12998/wjcc.v9.i16.4090] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v9/i16/4090.htm |
| Number | Citing Articles |
| 1 |
Zirui Wang, Cong Wang, Xiaohua Fei, Haixing Wu, Peiqin Niu, Changxing Shen. Thymalfasin therapy accelerates COVID-19 pneumonia rehabilitation through anti-inflammatory mechanisms. Pneumonia 2023; 15(1) doi: 10.1186/s41479-023-00116-6
|
| 2 |
|
| 3 |
Mohamed A. A. Hussein, Hosni A. M. Hussein, Ali A. Thabet, Karim M. Selim, Mervat A. Dawood, Ahmed M. El-Adly, Ahmed A. Wardany, Ali Sobhy, Sameh Magdeldin, Aya Osama, Ali M. Anwar, Mohammed Abdel-Wahab, Hussam Askar, Elsayed K. Bakhiet, Serageldeen Sultan, Amgad A. Ezzat, Usama Abdel Raouf, Magdy M. Afifi. Human Wharton’s Jelly Mesenchymal Stem Cells Secretome Inhibits Human SARS-CoV-2 and Avian Infectious Bronchitis Coronaviruses. Cells 2022; 11(9): 1408 doi: 10.3390/cells11091408
|
| 4 |
Yiying Xue, Husheng Mei, Yisa Chen, James D. Griffin, Qingsong Liu, Ellen Weisberg, Jing Yang. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2. MedComm 2023; 4(3) doi: 10.1002/mco2.254
|